Literature DB >> 11404625

Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx.

J G Spector1, D G Sessions, B H Haughey, K S Chao, J Simpson, S El Mofty, C A Perez.   

Abstract

OBJECTIVE: To determine the impact of delayed regional metastases, distant metastases, and second primary tumors on the therapeutic outcomes in squamous cell carcinomas of the larynx and hypopharynx. STUDY
DESIGN: Chart review and statistical analysis.
METHODS: A retrospective tumor registry analysis was made of patients with squamous cell carcinomas of the larynx and hypopharynx who were treated with curative intent in the Department of Otolaryngology-Head and Neck Surgery and the Radiation Oncology Center of the Washington University School of Medicine (St. Louis, MO) between January 1971 and December 1991 and developed delayed regional metastases (2 y after treatment), distant metastases, and second primary malignancies.
RESULTS: In 2550 patients, the mean age (59.8 y), sex (8.5 male patients and 1 female patient), and tumor differentiation did not affect the incidence of delayed distant, regional, or second primary malignancies. The overall incidence of delayed regional metastases was 12.4% (317/2550 patients); distant metastases, 8.5% (217/2550); and second primary tumors, 8.9% (228/2550), with a 5-year disease-specific survival of 41%, 6.4%, and 35%, respectively. Second primary malignancies were not statistically related to the origin of the primary tumor, tumor staging, or delayed regional and distant metastases (P =.98). Delayed regional metastases and distant metastases were related to advanced primary disease (T4 stage), lymph node metastases (node positive [N+]), tumor location (hypopharynx), and locoregional tumor recurrence (P < or =.028). Advanced regional metastases at initial diagnosis (N2 and N3 disease) increased the incidence of delayed and distant metastases threefold (P =.017). These two metastatic parameters were significantly greater in hypopharyngeal tumors than in laryngeal tumors (P =.037). The incidences of delayed regional metastases by anatomical location of the primary tumor were as follows: glottic, 4.4%; supraglottic, 16%; subglottic, 11.5%; aryepiglottic fold, 21.9%; pyriform sinus, 31.1%; and posterior hypopharyngeal wall, 18.5%. The incidences of distant metastases were as follows: glottic, 4%; supraglottic, 3.7%; subglottic, 14%; aryepiglottic fold, 16%; pyriform fossa, 17.2%; and posterior hypopharyngeal wall, 17.6%. Seventeen hypopharyngeal tumors (2%) presented with M1 disease. Delayed regional metastases to the ipsilateral treated neck had a significantly worse survival prognosis than delayed metastases to the contralateral nontreated neck (P =.001).
CONCLUSIONS: Conclusions are as follows: 1) The incidence of second primary tumors is independent from the primary tumor staging and distant and delayed regional metastases. The highest incidence occurred in patient groups with the highest disease-free survival rates (P =.0378). 2) Highest incidence of delayed and distant metastases occurred in hypopharyngeal tumors and was three times greater than in laryngeal cancers (P =.028). 3) Salvage therapeutic rates were poor for delayed metastases to the ipsilateral treated nodes and distant metastases as compared with contralateral neck metastases and second primary tumors (P =.001). 4) Delayed and distant lymph node metastases were significantly higher in advanced primary disease (T4 stage), locoregional recurrences, and regional disease (N2 and N3) (P =.028) in both the larynx and hypopharynx. 5) The higher incidence of delayed and distant metastatic disease was related to more advanced initial tumor presentation in hypopharyngeal cancer as compared with laryngeal cancer (P =.039). 6) Incidence of distant metastases was greatest between 1.5 and 6 years after initial treatment with a mean incidence being less than or equal to 3.2 years.

Entities:  

Mesh:

Year:  2001        PMID: 11404625     DOI: 10.1097/00005537-200106000-00028

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  55 in total

1.  Temporal characterization of lymphatic metastasis in an orthotopic mouse model of oral cancer.

Authors:  Peter Szaniszlo; Susan M Fennewald; Suimin Qiu; Carla Kantara; Tuya Shilagard; Gracie Vargas; Vicente A Resto
Journal:  Head Neck       Date:  2014-01-27       Impact factor: 3.147

2.  The role of tumor size and patient's age as prognostic factors in laryngeal cancer.

Authors:  K Markou; J Goudakos; S Triaridis; J Konstantinidis; V Vital; A Nikolaou
Journal:  Hippokratia       Date:  2011-01       Impact factor: 0.471

3.  Clinical and molecular prognostic factors in operable laryngeal cancer.

Authors:  Konstantinos Vlachtsis; Angelos Nikolaou; Konstantinos Markou; George Fountzilas; Ioannis Daniilidis
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-03-01       Impact factor: 2.503

4.  The follow-up of patients with head and neck cancer: an analysis of 1,039 patients.

Authors:  P Kothari; A Trinidade; R J D Hewitt; A Singh; P O'Flynn
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-12-31       Impact factor: 2.503

Review 5.  Metastatic disease in head & neck oncology.

Authors:  Paolo Pisani; Mario Airoldi; Anastasia Allais; Paolo Aluffi Valletti; Mariapina Battista; Marco Benazzo; Roberto Briatore; Salvatore Cacciola; Salvatore Cocuzza; Andrea Colombo; Bice Conti; Alberto Costanzo; Laura Della Vecchia; Nerina Denaro; Cesare Fantozzi; Danilo Galizia; Massimiliano Garzaro; Ida Genta; Gabriela Alejandra Iasi; Marco Krengli; Vincenzo Landolfo; Giovanni Vittorio Lanza; Mauro Magnano; Maurizio Mancuso; Roberto Maroldi; Laura Masini; Marco Carlo Merlano; Marco Piemonte; Silvia Pisani; Adriele Prina-Mello; Luca Prioglio; Maria Gabriella Rugiu; Felice Scasso; Agostino Serra; Guido Valente; Micol Zannetti; Angelo Zigliani
Journal:  Acta Otorhinolaryngol Ital       Date:  2020-04       Impact factor: 2.124

6.  Predictive and prognostic factors for patients with locoregionally advanced laryngeal carcinoma treated with surgical multimodality protocol.

Authors:  Gorkem Eskiizmir; Gokce Tanyeri Toker; Onur Celik; Kivanc Gunhan; Ayca Tan; Hulya Ellidokuz
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-10       Impact factor: 2.503

7.  Impact of total lesion glycolysis measured by 18F-FDG-PET/CT on overall survival and distant metastasis in hypopharyngeal cancer.

Authors:  Hidenori Suzuki; Masami Nishio; Hayao Nakanishi; Nobuhiro Hanai; Hitoshi Hirakawa; Takeshi Kodaira; Tsuneo Tamaki; Yasuhisa Hasegawa
Journal:  Oncol Lett       Date:  2016-06-23       Impact factor: 2.967

8.  Potential biomarkers for paclitaxel sensitivity in hypopharynx cancer cell.

Authors:  Cheng-Zhi Xu; Run-Jie Shi; Dong Chen; Yi-Yuan Sun; Qing-Wei Wu; Tao Wang; Pei-Hua Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

9.  Connexin 43 (Cx43) Expression in Laryngeal Squamous Cell Carcinomas: Preliminary Data on Its Possible Prognostic Role.

Authors:  Lidia Puzzo; Rosario Caltabiano; Rosalba Parenti; Serena Trapasso; Eugenia Allegra
Journal:  Head Neck Pathol       Date:  2016-01-09

Review 10.  Causes of death of patients with laryngeal cancer.

Authors:  Alfio Ferlito; Missak Haigentz; Patrick J Bradley; Carlos Suárez; Primož Strojan; Gregory T Wolf; Kerry D Olsen; William M Mendenhall; Vanni Mondin; Juan P Rodrigo; Carsten C Boedeker; Marc Hamoir; Dana M Hartl; Jennifer L Hunt; Kenneth O Devaney; Lester D R Thompson; Alessandra Rinaldo; Robert P Takes
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-04-17       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.